A novel platinum complex of the histone deacetylase inhibitor belinostat: Rational design, development and in vitro cytotoxicity

被引:31
作者
Parker, James P. [1 ]
Nimir, Hassan [2 ]
Griffith, Darren M. [1 ]
Duff, Brian [3 ]
Chubb, Anthony J. [4 ]
Brennan, Marian P. [5 ]
Morgan, Maria P. [5 ]
Egan, Denise A. [3 ]
Marmion, Celine J. [1 ]
机构
[1] Royal Coll Surgeons Ireland, Dept Pharmaceut & Med Chem, Ctr Synth & Chem Biol, Dublin 2, Ireland
[2] Univ Qatar, Coll Arts & Sci, Dept Chem & Earth Sci, Doha, Qatar
[3] Dublin Inst Technol, Dept Sci, Ctr Pharmaceut Res & Dev, Dublin 24, Ireland
[4] Natl Univ Ireland Univ Coll Dublin, Complex & Adapt Syst Lab, Dublin 4, Ireland
[5] Royal Coll Surgeons Ireland, Dublin 2, Ireland
基金
爱尔兰科学基金会;
关键词
Platinum; Histone deacetylases; Histone deacetylase inhibitors; Belinostat; Anti-cancer; Cytotoxicity; CRYSTAL-STRUCTURE; ANTICANCER AGENT; OVARIAN-CANCER; SOLID TUMORS; ACID; CARBOPLATIN; HYDROLYSIS; RESISTANCE; CISPLATIN; LYMPHOMA;
D O I
10.1016/j.jinorgbio.2013.03.011
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The successful design and synthesis of a novel Pt complex of the histone deacteylase inhibitor belinostat are reported. Molecular modelling assisted in the identification of a suitable malonate derivative of belinostat (mal-p-Bel) for complexation to platinum. Reaction of [Pt(NH3)(2)(H2O)(2)](NO3)(2) with the disodium salt of mal-p-Bel gave cis-[Pt(NH3)(2)(mal-p-Bel(-2H))] (where -(2H) indicates that mal-p-Bel is doubly deprotonated) in excellent yield. An in vitro cytotoxicity study revealed that cis-[Pt(NH3)(2)(mal-p-Bel(-2H)] possesses (i) considerable cytotoxicity against reported ovarian cancer cell lines, (ii) enhanced cytotoxicity relative to the previously reported Pt histone deacetylase inhibitor conjugate, cis-[Pt-II(NH3)(2)(malSAHA(-2H))] and (iii) favourable cyto-selective properties as compared to cisplatin and belinostat. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:70 / 77
页数:8
相关论文
共 50 条
  • [1] Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat
    To, Kenneth Kin-Wah
    Tong, Wing-Sum
    Fu, Li-wu
    LUNG CANCER, 2017, 103 : 58 - 65
  • [2] Novel trans-platinum complexes of the histone deacetylase inhibitor valproic acid; synthesis, in vitro cytotoxicity and mutagenicity
    Griffith, Darren M.
    Duff, Brian
    Suponitsky, Kyrill Y.
    Kavanagh, Kevin
    Morgan, Maria P.
    Egan, Denise
    Marmion, Celine J.
    JOURNAL OF INORGANIC BIOCHEMISTRY, 2011, 105 (06) : 793 - 799
  • [3] Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor
    Gimsing, Peter
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (04) : 501 - 508
  • [4] Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer
    Dmitriy I Dovzhanskiy
    Stefanie M Arnold
    Thilo Hackert
    Ina Oehme
    Olaf Witt
    Klaus Felix
    Nathalia Giese
    Jens Werner
    BMC Cancer, 12
  • [5] Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer
    Dovzhanskiy, Dmitriy I.
    Arnold, Stefanie M.
    Hackert, Thilo
    Oehme, Ina
    Witt, Olaf
    Felix, Klaus
    Giese, Nathalia
    Werner, Jens
    BMC CANCER, 2012, 12
  • [6] Proteomic profiling of human colon cancer cells treated with the histone deacetylase inhibitor belinostat
    Beck, Hans Christian
    Petersen, Jorgen
    Nielsen, Soren Jensby
    Morszeck, Christian
    Jensen, Peter B.
    Sehested, Maxwell
    Grauslund, Morten
    ELECTROPHORESIS, 2010, 31 (16) : 2714 - 2721
  • [7] Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer
    Martin, Darryl T.
    Hoimes, Christopher J.
    Kaimakliotis, Hristos Z.
    Cheng, Christopher J.
    Zhang, Ke
    Liu, Jingchun
    Wheeler, Marcia A.
    Kelly, W. Kevin
    Tew, Greg N.
    Saltzman, W. Mark
    Weiss, Robert M.
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2013, 9 (08) : 1124 - 1134
  • [8] Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro
    Peters, Godefridus J.
    van Gemert, Frank P. A.
    Kathmann, Ietje
    Reddy, Guru
    Cillessen, Saskia A. G. M.
    Jansen, Gerrit
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
  • [9] Antitumor platinum(IV) derivatives of carboplatin and the histone deacetylase inhibitor 4-phenylbutyric acid
    Almotairy, Awatif Rashed Z.
    Gandin, Valentina
    Morrison, Liam
    Marzano, Cristina
    Montagner, Diego
    Erxleben, Andrea
    JOURNAL OF INORGANIC BIOCHEMISTRY, 2017, 177 : 1 - 7
  • [10] Romidepsin: a novel histone deacetylase inhibitor for cancer
    Bertino, Erin M.
    Otterson, Gregory A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (08) : 1151 - 1158